Dianthus Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2015-01-01
- Employees
- 53
- Market Cap
- -
- Website
- https://www.magentatx.com
- Introduction
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
Dianthus Therapeutics Completes Enrollment in Phase 2 MaGic Trial for Generalized Myasthenia Gravis Treatment
• Dianthus Therapeutics has successfully enrolled 65 patients in its Phase 2 MaGic trial of DNTH103 for generalized Myasthenia Gravis, exceeding the target of 60 patients with top-line results expected in September 2025.
• DNTH103 is a monoclonal antibody designed to selectively inhibit the classical complement pathway by targeting the C1s protein, potentially offering patients a convenient self-administered subcutaneous injection dosed once every two weeks.
• The company is building a neuromuscular franchise with DNTH103, which is also being evaluated in Phase 3 trials for Chronic Inflammatory Demyelinating Polyneuropathy and Phase 2 trials for Multifocal Motor Neuropathy, with results expected in the second half of 2026.
Complement Inhibitors Show Promise in Diverse Clinical Trials
• The complement inhibitors market is experiencing growth due to increased understanding of the complement system's role in rare and chronic diseases.
• Over 40 companies are actively developing more than 50 complement inhibitor therapies, targeting conditions like PNH, aHUS and Guillain-Barré syndrome.
• Clinical trials are underway for novel inhibitors like Gefurulimab, ANX005 and DNTH103, showing potential in myasthenia gravis and multifocal motor neuropathy.
• Recent FDA clearances and orphan drug designations highlight the increasing regulatory support for complement-targeted therapies, fostering innovation.
© Copyright 2025. All Rights Reserved by MedPath